Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors

Bing Yang1,*, Yu-Shun Yang1,2,*, Na Yang1,2, Guigen Li3 & Hai-Liang Zhu1

A series of novel dioxin-containing pyrazoline derivatives with thiourea skeleton have been designed, synthesized and evaluated for their EGFR/HER-2 inhibitory and anti-proliferation activities. A majority of them displayed selective HER-2 inhibitory activity against EGFR inhibitory activity. Compound C20 displayed the most potent activity against HER-2 and MDA-MB-453 human breast cancer cell line (IC50 = 0.03 μM and GI50 = 0.15 μM), being slightly more potent than the positive control Erlotinib (IC50 = 0.16 μM and GI50 = 1.56 μM) and comparable with Lapatinib (IC50 = 0.01 μM and GI50 = 0.03 μM). It is a more exciting result that C20 was over 900 times more potent against HER-2 than against EGFR while this value was 0.19 for Erlotinib and 1.00 for Lapatinib, indicating high selectivity. The results of docking simulation indicate that the dioxin moiety occupied the exit of the active pocket and pushed the carbothioamide deep into the active site. QSAR models have been built with activity data and binding conformations to begin our work in this paper as well as to provide a reliable tool for reasonable design of EGFR/HER-2 inhibitors in future.

Cancer chemotherapy, due to the progress of medical researches, steps into a new era in which molecular-targeted therapeutic methods bring in higher selective and less toxic agents compared to the old drugs1,2. Among the receptor protein tyrosine kinases (RPTKs) which is a hot spot3, epidermal growth factor receptor (EGFR) kinase has been identified as a critical role in cancer. Although EGFR family comprises four members4, deregulation of growth-factor signaling due to hyper-activation of EGFR and HER-2 has been primarily seen in several cancer types5–8. However, EGFR inhibitors face three predicaments: 1) Even EGFR is inhibited, the overexpress of HER-2 can still open the downstream pathway9; 2) Point mutation of EGFR exons 19 and 20 may cause reduced sensitivity to drugs10; 3) A tremendous downstream pathway may cause toxicity11–13. Thus, unique HER-2 inhibitors with high selectivity and low toxicity, instead of pan blockers14, become critically significant15–17.

The previous 3D-QSAR models of pyrazoline moiety provided a result that three aryl ones suited EGFR better while thiourea backbone fitted HER-2 better relatively in pyrazoline derivatives (Fig. 1)18. To acquire compounds remaining HER-2 inhibitory activity but weakening that of EGFR, ring A (3-position group of pyrazoline) should disobey the previous model which meant introducing electron-donating groups at para and meta positions. Thiourea backbone was reserved also because of its related activity19–21. Oxygen heterocyclic ring was introduced due to its reported HER-2 inhibitory activity22. Five-member or six-member rings were choices because larger ring meant less potency. However, we have to consider the interference of telomerase inhibiting while using this backbone. Unfortunately EGFR/HER-2 should remain regular independently, thus bi-inhibitor is less recommended than selective ones in such a situation23. According to the previous report, compared with five-member ring, six-member one showed weaker telomerase inhibitory activity24. Thus, the basic structure of compounds in this paper was settled.

1State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China. 2Institute of Chemistry and BioMedical Sciences, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to G.L. (email: guigenli@nju.edu.cn) or H.-L.Z. (email: zhuhl@nju.edu.cn)
According to the studies above, a novel series of 4,5-dihydro-1\textsubscript{H}-pyrazole derivatives containing thiourea skeleton and dioxin structure was designed as potential HER-2 selective inhibitors and predicted to have a positive progress with a sound cancer therapeutic benefit.

**Results**

**Preliminary Calculation.** Before synthesis, the target series was amplified into four series (Fig. 2) to examine their binding energy with EGFR and HER-2, respectively. Molecular docking was conducted to predict the binding energy (CDOCKER INTERACTION ENERGY in CDOCKER protocol in Discovery Studio 3.5) between the four series and EGFR/HER-2. EGFR with Erlotinib (PDB code: 1M17)\textsuperscript{25} and HER-2 with ligand 03Q (PDB code: 3PQP)\textsuperscript{26} were used respectively. The average EGFR binding energy of series I, II, III, IV were $-36.3199 \text{ kcal/mol}$, $-36.4076 \text{ kcal/mol}$, $-40.7584 \text{ kcal/mol}$, $-40.4444 \text{ kcal/mol}$. Meanwhile, the top HER-2 binding energy of series I, II, III, IV were $-52.8093 \text{ kcal/mol}$, $-51.7253 \text{ kcal/mol}$, $-50.8926 \text{ kcal/mol}$, $-49.7947 \text{ kcal/mol}$. Aiming at acquiring selective HER-2 inhibitors, we prefer Series I after we additionally compared the bottom HER-2 binding energy of series I and II ($-40.9818 \text{ kcal/mol}$ vs $-37.4009 \text{ kcal/mol}$).

Since ADMET properties are important parameters of pharmacokinetics\textsuperscript{27,28}, the ADMET prediction of all 80 compounds was provided (Fig. 3). The results were satisfactory. Thus, we chose Series I (Fig. 4 and Table 1) as target compounds after the preliminary analysis above. The general synthesis method was also organized in Fig. 4.
Kinase inhibitory activity and cell proliferation. All the synthesized compounds C1–C20 were evaluated for their EGFR and HER-2 inhibitory activity. The results were expressed as concentrations of IC50 (the half maximal inhibitory concentration of EGFR and HER-2 mediated autophosphorylation) and GI50 (the half maximal inhibitory concentration of MCF-7 human breast cancer cell line and MDA-MB-453 human breast cancer cell line growth), presented in Table 2. A general glance of the bioactivity as well as SI (the selectivity index of EGFR/HER-2) suggested that most of this series were potential HER-2 inhibitors with merely mediocre EGFR inhibitory activity.
The results were expressed as IC50 values, presented in Table 3. Thus, these results further validated the selectivity of the compounds against HER-2 as well as the positive correlation between bioactivities against HER-2 and MDA-MB-453 (Fig S2).

Table 2. EGFR and HER-2 inhibitory activity and selectivity index with anti-proliferation activity of the synthesized compounds (C1-C20).

| Compounds | IC50 (μM) | IC50 (μM) | GI50 (μM) | GI50 (μM) | SI |
|-----------|-----------|-----------|-----------|-----------|----|
|           | EGFR      | HER-2     | MDA-MB-453 | MCF-7     |    |
| C1        | 21.85 ± 2.03 | 16.01 ± 1.45 | 63.4 ± 6.12 | 10.03 ± 0.91 | 1.36 |
| C2        | 2.94 ± 0.26  | 0.56 ± 0.05  | 2.20 ± 0.18  | 4.68 ± 0.42  | 5.25 |
| C3        | 4.42 ± 0.35  | 7.18 ± 0.65  | 19.9 ± 1.84  | 5.30 ± 0.49  | 0.62 |
| C4        | 59.33 ± 5.58 | 125.3 ± 10.2 | >300        | 185.4 ± 17.8 | 0.47 |
| C5        | 43.58 ± 4.10 | 86.55 ± 8.05 | 135.1 ± 11.1 | 57.2 ± 5.36  | 0.50 |
| C6        | 4.49 ± 0.41  | 0.06 ± 0.004 | 0.20 ± 0.02  | 4.95 ± 0.43  | 74.8 |
| C7        | 9.45 ± 0.88  | 62.85 ± 5.67 | >300        | 16.8 ± 0.98  | 0.15 |
| C8        | 8.63 ± 0.78  | 0.45 ± 0.04  | 1.69 ± 0.15  | 5.64 ± 0.52  | 19.2 |
| C9        | 65.16 ± 5.88 | 0.37 ± 0.03  | 1.38 ± 0.12  | 56.2 ± 5.41  | 176.1 |
| C10       | 37.95 ± 3.75 | 0.08 ± 0.006 | 0.25 ± 0.02  | 18.2 ± 1.71  | 474.4 |
| C11       | 47.83 ± 4.54 | 1.90 ± 0.15  | 11.9 ± 1.05  | 28.5 ± 2.80  | 25.2 |
| C12       | 53.82 ± 5.12 | 0.84 ± 0.07  | 5.31 ± 0.48  | 33.9 ± 3.21  | 64.1 |
| C13       | 82.03 ± 7.84 | 0.80 ± 0.07  | 3.24 ± 0.30  | 123.3 ± 11.2 | 102.5 |
| C14       | 84.26 ± 7.81 | 1.23 ± 0.10  | 9.12 ± 0.89  | 134.7 ± 11.6 | 68.5 |
| C15       | 27.50 ± 2.46 | 0.29 ± 0.02  | 0.95 ± 0.08  | 12.1 ± 1.17  | 94.8 |
| C16       | 10.20 ± 0.94 | 0.13 ± 0.01  | 0.36 ± 0.03  | 5.99 ± 0.55  | 78.5 |
| C17       | 79.71 ± 7.01 | 0.21 ± 0.02  | 0.55 ± 0.02  | 96.4 ± 9.22  | 379.6 |
| C18       | 34.03 ± 3.08 | 0.96 ± 0.08  | 8.68 ± 0.84  | 15.2 ± 1.40  | 35.4 |
| C19       | 195.5 ± 18.5 | 12.04 ± 1.02 | 33.4 ± 2.95  | >300        | 16.3 |
| C20       | 28.56 ± 2.52 | 0.03 ± 0.002 | 0.15 ± 0.01  | 11.9 ± 1.06  | 952.0 |
| Erlotinib  | 0.03 ± 0.003 | 0.16 ± 0.01  | 1.56 ± 0.14  | 0.08 ± 0.006 | 0.19 |
| Lapatinib  | 0.01 ± 0.001 | 0.01 ± 0.001 | 0.03 ± 0.002 | 3.12 ± 0.24  | 1.00 |

Linear regression (Fig S1) was conducted to ensure the GI50 values of these compounds shared a similar tendency with their relevant IC50 values, checking that the anti-proliferative effect was produced by inhibitory action against HER-2. As a result, MDA-MB-453 cell line was notably positive correlated to HER-2 (R square = 0.924) while MCF-7 cell line showed no obvious correlation with HER-2 (R square = 0.239). This inference agreed with the relative expression levels of HER-2 in the two cell lines.

Out of the twenty synthesized compounds, C20 displayed the most potent activity against HER-2 and MDA-MB-453 cell line (IC50 = 0.03 μM and GI50 = 0.15 μM), being comparable with the positive control Erlotinib (IC50 = 0.16 μM and GI50 = 1.56 μM) and Lapatinib (IC50 = 0.01 μM and GI50 = 0.03 μM). A more exciting result was that C20 was 952 times more potent against HER-2 than against EGFR, because this value was 0.19 for Erlotinib and 1.00 for Lapatinib. This fact indicated that our modification led to favorable effect in both inhibitory activity and selectivity.

Flow Cytometry. We conducted the flow cytometry (FCM) (Fig. 5) to explain the inhibitory activity of the lead compound C20. The results indicated that the compound could induce apoptosis of activated MDA-MB-453 cell line in a dose-dependent manner. With the cells treated with 0.05, 0.1 and 0.2 μM of compounds for 24 h, the percentage of apoptosis by Annexin V-FITC/PI staining was increased correspondingly in a dose-dependent manner.

Western Blot. The corresponding p-HER-2 and p-EGFR levels of MDA-MB-453 dealt by C20 were measured by Western blot (Fig. 6). With the increasing of C20 levels, p-HER-2 levels showed gradually trend of decrease. A corresponding increase of Caspase3 levels indicated that this effect could induce apoptosis. Consequently, compound C20 could directly bind to HER-2, and lower its phosphorylation level. The variation of p-EGFR levels is unconspicuous because the tested concentrations of compound is far below that could cause inhibitory activity of EGFR.

BLI Assay. BLI assay was conducted between labeled compound C20 and HER-2. The result was shown in Fig. 7. The calculated Kd by the system itself was 1.87 ± 0.14 × 10⁻⁹ M, indicating a relatively strong interaction on small molecule level.

Broadened kinase selectivity. To further expand the discussion of selectivity, we tested the inhibitory activities of representative compounds (C9, C10, C13, C15, C17 and C20) against three other related kinases. The three kinases chosen were: VEGFR2 (activating similar pathways and often studied together), HER-3 (also called erbb-3, belonging to EGFR family but activating different pathway), FAK (a downstream kinase of EGFR but in a unique pathway). The results were expressed as IC50 values, presented in Table 3. Thus, these results further validated the selectivity of the compounds against HER-2 as well as the positive correlation between bioactivities against HER-2 and MDA-MB-453 (Fig S2).
Toxicity test. Besides, the cytotoxic activity of the compounds were evaluated on a mouse embryonic fibroblast cell line (NIH-3T3) using the MTT assay\textsuperscript{29}. The results were summarized in Table 4 as well as hemolytic activities. It can be concluded that the selected compounds with potent inhibitory activity and high selectivity were low toxic, which was comparable to the positive control DDCP\textsuperscript{30}.

Figure 5. MDA-MB-453 cell line was cultured with various concentrations of C20 for 24 h. Cells were stained by Annexin V-FITC/PI and apoptosis was analyzed by flow cytometry in a dose-dependent manner. (A) Control; (B) 0.05 \(\mu\)M; (C) 0.1 \(\mu\)M; (D) 0.2 \(\mu\)M.

Figure 6. Western blot was performed to detect the effect of compound C20 on p-HER-2 and p-EGFR.
Docking Study. Molecular docking is a procedure in which molecular modeling techniques are used to predict how a protein (enzyme) interacts with small molecules (ligands)\(^3\). Although the CDOCKER protocol in Discovery Studio 3.5 (Discovery Studio 3.5, Accelrys, Inc. San Diego, CA) was used before synthesis to help design our basic backbone, the results could also be used to explore the interaction between compounds and EGFR/HER-2 as well as to visualize the probable binding mode after bioassay. After preparing the receptor and ligands, the site sphere was selected based on the ligand binding location. The binding models of the most potent compounds with corresponding targets were depicted in Fig. 8 (C\(^{20}\) with 3PP0; C\(^{20}\) and C\(^{2}\) with 1M17, respectively).

Not a surprise, the CDocker Interaction Energy (interaction energy between the ligand and the receptor) and the CDocker Energy (energy of the ligand - receptor complexes) agreed with the inhibitory trend for all the synthesized compounds. In the binding model (Fig. 8), compound C\(^{20}\) is nicely bound to 3PP0 via two hydrogen bonds. One of the amino hydrogen of carbothioamide contributes to both hydrogen bonding interaction with the main chain of ALA751 (N-H … O: 2.235 Å, 113.632°) and the main chain of LEU796 (N-H … O: 2.242 Å, 132.736°), being a probable explanation for its nice activity. This result indicated that the molecular interactions between both rings of compound and surrounding residues contributed to the strong interaction between the carbothioamide moiety and corresponding residues. When the rings changed, the interactions on the carbothioamide varied. In the EGFR model, compound C\(^{2}\) is nicely bound to 1M17 via two hydrogen bonds and two \(\pi\)-cation interactions. The sulfur atom of carbothioamide contributes to one of the hydrogen bonding interaction (S … H-O: 2.314 Å, 160.269°) with the hydrogen atom on the side chain of THR766. Besides, one of the amino hydrogen of carbothioamide contributes to the hydrogen bonding interaction with the main chain of GLN767 (N-H … O:

Figure 7. BLI assay of HER-2. Representative time courses of the interference signals elicited by labeled compound C\(^{20}\). Data are representative of three separate experiments.

Table 3. Kinases inhibitory activities (VEGFR2, FAK and HER-3) of representative compounds (C9, C10, C13, C15, C17 and C20).

| Compounds | IC50(μM) VEGFR-2 | IC50(μM) FAK | IC50(μM) HER-3 |
|-----------|------------------|--------------|----------------|
| C9        | 11.5 ± 1.07      | 36.1 ± 3.21  | 6.32 ± 0.58    |
| C10       | 6.91 ± 0.64      | 64.0 ± 5.95  | 10.7 ± 0.96    |
| C13       | 25.8 ± 2.41      | 36.5 ± 3.42  | 2.46 ± 0.23    |
| C15       | 8.75 ± 0.77      | 40.3 ± 3.88  | 17.9 ± 1.48    |
| C17       | 5.16 ± 0.50      | 30.1 ± 2.76  | 8.45 ± 0.78    |
| C20       | 18.4 ± 1.74      | 56.2 ± 5.48  | 5.20 ± 0.46    |

Table 4. Hemolytic activities and cytotoxicity of selected compounds. *Lytic concentration 30%.

| Compounds | Hemolysis (LC30(mg/mL)) | Cytotoxicity (NIH3T3) (GL50(μM)) |
|-----------|--------------------------|----------------------------------|
| C9        | >10                      | 199.1 ± 1.60                     |
| C10       | >10                      | 203.8 ± 3.05                     |
| C13       | >10                      | 148.5 ± 2.02                     |
| C15       | >10                      | 154.1 ± 1.75                     |
| C17       | >10                      | 185.4 ± 3.15                     |
| C20       | >10                      | 274.4 ± 3.61                     |
| DCCP      | >10                      | 125.8 ± 3.12                     |

Docking Study. Molecular docking is a procedure in which molecular modeling techniques are used to predict how a protein (enzyme) interacts with small molecules (ligands)\(^3\). Although the CDOCKER protocol in Discovery Studio 3.5 (Discovery Studio 3.5, Accelrys, Inc. San Diego, CA) was used before synthesis to help design our basic backbone, the results could also be used to explore the interaction between compounds and EGFR/HER-2 as well as to visualize the probable binding mode after bioassay. After preparing the receptor and ligands, the site sphere was selected based on the ligand binding location. The binding models of the most potent compounds with corresponding targets were depicted in Fig. 8 (C\(^{20}\) with 3PP0; C\(^{20}\) and C\(^{2}\) with 1M17, respectively).

Not a surprise, the CDocker Interaction Energy (interaction energy between the ligand and the receptor) and the CDocker Energy (energy of the ligand - receptor complexes) agreed with the inhibitory trend for all the synthesized compounds. In the binding model (Fig. 8), compound C\(^{20}\) is nicely bound to 3PP0 via two hydrogen bonds. One of the amino hydrogen of carbothioamide contributes to both hydrogen bonding interaction with the main chain of ALA751 (N-H … O: 2.235 Å, 113.632°) and the main chain of LEU796 (N-H … O: 2.242 Å, 132.736°), being a probable explanation for its nice activity. This result indicated that the molecular interactions between both rings of compound and surrounding residues contributed to the strong interaction between the carbothioamide moiety and corresponding residues. When the rings changed, the interactions on the carbothioamide varied. In the EGFR model, compound C\(^{2}\) is nicely bound to 1M17 via two hydrogen bonds and two \(\pi\)-cation interactions. The sulfur atom of carbothioamide contributes to one of the hydrogen bonding interaction (S … H-O: 2.314 Å, 160.269°) with the hydrogen atom on the side chain of THR766. Besides, one of the amino hydrogen of carbothioamide contributes to the hydrogen bonding interaction with the main chain of GLN767 (N-H … O:
2.236 Å, 152.083°). Meanwhile, the two π–cation interactions are formed between the naphthalin ring and LYS721 (4.199 Å and 5.490 Å). All these interactions conformed to the relatively nice EGFR inhibitory activity of C2. In comparison, however, C20 is bound to 1M17 via merely one hydrogen bond. The only hydrogen bond is formed between the dioxin ring and side chain of THR766 (O—H–O: 2.109 Å, 150.656°). Thus, the binding pattern might suggest the high selectivity of C20.

Moreover, the receptor surface model (Shown in Fig. 9) was conducted to reveal the possible situation of the compounds embedded in the active pocket. The dioxin moiety occupied the exit of the active pocket including VAL734, ALA751, SER783, LEU796, CYS805, LEU852 and THR862, pushed the carbothioamide deep into the active site, confirming the success of structural modification.

**QSAR model.** By using the Create 3D QSAR protocol of Discovery Studio 3.5, twenty synthesized compounds with definite IC50 values against HER-2 were selected as the model dataset. By convention, we used the pIC50 scale (−log IC50), in which higher value indicates exponentially greater potency, to measure the inhibitory activity. The training set and testing set were chosen by the Diverse Molecules method in Discovery Studio 3.5. To ensure a good alignment, we chose the alignment conformation of each molecule with lowest energy in the docked results of CDOCKER protocol. Besides, we applied the alignment by the substructure C1 before building the QSAR model. With the correlation coefficient r² between observed activity of testing set and training set found to be 0.722, the QSAR model we built is acceptable (larger than 0.4). Compounds C6 and C16 with -OBn

---

**Figure 8.** (A) 2D molecular docking model of compound C20 with 3PP0. (B) 3D model of the interaction between compound C20 and 3PP0 binding site. (C) 2D molecular docking model of compound C20 with 1M17. (D) 2D molecular docking model of compound C2 with 1M17. The H-bonds are displayed as dotted lines and the amino acid they act on are labeled in green. The π–cation interactions are shown as orange lines.

**Figure 9.** The receptor surface model with C20 for HER-2.
pounds were with appropriate size should be involved in designing this kind of inhibitors. The corresponding compounds C4 existed a suitable substitute, for the extra benzene ring extruded the steric structure backbone but phenyl group was included. For single group with substituted phenyl group to analyze the substitutes. Benzyloxyphenyl group was temporarily skipped consequently preliminary SAR (Structure Activity Relationship) studies were performed. Initially, we fixed the R modification. ortho-positions need electron-withdrawing groups, the size should be more strictly controlled within two carbon positions while Naphthalen-1-yl group overcome the disadvantage of ortho-positions need electron-withdrawing groups, the size should be more strictly controlled within two carbon units. The 3D QSAR model agrees with the inhibitory activity well and provide us the direction of further modification.

Discussion
To conclude, a series of novel dioxin-containing pyrazoline derivatives with thiourea skeleton have been designed, synthesized and evaluated for their EGFR/HER-2 inhibitory and anti-proliferation activities. A majority of them displayed selective HER-2 inhibitory activity against EGFR inhibitory activity. Compound C20 displayed the most potent activity against HER-2 and MDA-MB-453 human breast cancer cell line (IC50 = 0.03 μM and GI50 = 0.15 μM), being slightly more potent than the positive control Erlotinib (IC50 = 0.16 μM and GI50 = 1.56 μM) and comparable with Lapatinib (IC50 = 0.01 μM and GI50 = 0.03 μM). It is a more exciting result that C20 was over 900 times more potent against HER-2 than against EGFR while this value was 0.19 for Erlotinib and 1.00 for Lapatinib, indicating high selectivity. The results of docking simulation indicated that the dioxin moiety occupied the exit of the active pocket and pushed the carbothioamide deep into the active site. QSAR models were built with activity data and binding conformations to begin our work in this paper as well as to provide a reliable tool for reasonable design of EGFR/HER-2 inhibitors in future. To deduce how the HER-2 inhibitory activity was affected by the structure variation and modification, subsequently preliminary SAR (Structure Activity Relationship) studies were performed. Initially, we fixed the R group with substituted phenyl group to analyze the substitutes. Benzoxypyphenyl group was temporarily skipped for the extra benzene ring extruded the steric structure backbone but phenyl group was included. For single substitute, para-position generally showed better effect than meta-position nearly ruined the HER-2 inhibitory activity (C4, IC50 = 125.3 μM). As for para-position, we could perceive the tendency that -OMe > -CF3 > -SMe > -Me > -Br > -Cl > -I > -F > -H, inferring that an electron-donating substituent with appropriate size should be involved in designing this kind of inhibitors. The corresponding compounds were C10 (IC50 = 0.08 μM) > C17 (IC50 = 0.21 μM) > C15 (IC50 = 0.29 μM) > C9 (IC50 = 0.37 μM) > C13 (IC50 = 0.80 μM) > C12 (IC50 = 0.84 μM) > C14 (IC50 = 1.23 μM) > C11 (IC50 = 1.90 μM) > C1 (IC50 = 16.01 μM). Thus we could conjecture that appropriate size might be like -OMe or -CF3, for the order was -OMe > -CF3 > -SMe > -Me > -Br > -Cl > -I > -F instead of -OMe > -SMe > -Me > -Br > -Cl > -I > -F. As for meta-position, the inferred order was -Br > -Cl > -I > -F instead of -Cl > -I > -F > -Br. Therefore, the electronic factor might be more important than the steric factor. The corresponding compounds were C8 (IC50 = 0.45 μM) > C7 (IC50 = 62.85 μM) > C5 (IC50 = 86.55 μM). Meanwhile, for multi substitutes, only two hints could be inferred due to the sample size. One was that 6-F could make up the disadvantage of 2-F to a large extent with the corresponding result C18 (IC50 = 0.96 μM) > C4 (IC50 = 125.3 μM). The other was that a meta-group with suitable size could indeed contribute to the bioactivity when there already existed a suitable para-group, with the corresponding result C20 (IC50 = 0.03 μM) > C10 (IC50 = 0.08 μM). Secondly, Naphthalen-1-yl group showed better activity than Naphthalen-2-yl group as C2 (IC50 = 0.56 μM) > C3 (IC50 = 7.18 μM). Considering the discussion of substitutes above, the inference was that Naphthalen-2-yl group exceeded the steric limit of para- and meta- positions while Naphthalen-1-yl group overcome the disadvantage of ortho-position by stretching into a larger plane. Thirdly, although a heterocyclic ring (here it was furan) indicated

Figure 10. 3D-QSAR of 4,5-dihydro-1H-pyrazole derivatives containing dioxin moiety with thiourea skeleton for HER-2 (A,B). Red contours mean high electron density is expected to increase activity while blue contours mean low electron density is better. Green areas mean steric bulk is better while yellow areas mean small groups are helpful.
better effect than benzene ring with the corresponding result \( \text{C19} (\text{IC}_{50} = 12.04 \mu \text{M}) > \text{C1} (\text{IC}_{50} = 16.01 \mu \text{M}) \), the difficulty in introducing substitutes made this feeble superiority fade away. Finally, we came to benzoxoyphe-nyl group. This group distorted the original backbone no matter the situation was 3-OBn or 4-OBn. Although compounds with benzoxoyphenyl group were not that good as the others in the ADMET properties, both 3-OBn and 4-OBn showed admirable activity accidentally with the corresponding results \( \text{C6} (\text{IC}_{50} = 0.06 \mu \text{M}) \) and \( \text{C16} (\text{IC}_{50} = 0.13 \mu \text{M}) \) respectively. A possible explanation might be the conformational inversion according to the molecular overlap result. That might be an interesting direction in future research.

**Materials and Methods**

**Chemistry section.** The synthesized compounds \( \text{C1-C20} \) were all prepared in two steps. Firstly, 1-(2,3-dihy-drobenzo[b][1,4]dioxin-6-yl)ethan-1-one on treatment with different substituted benzaldehydes in presence of 50% NaOH were stirred at room temperature till reactions completed, yielding different analogues of chalcones (B). Secondly, thiosemicarbazide was added to participate the cyclization of the obtained analogues of chalcones (B), leading to the corresponding target compounds \( \text{C1-C20} \). All of the synthetic compounds gave satisfactory analytical and spectroscopic data, which were in full accordance with their depicted structures. (The detailed information is in Supplementary Information).

**Biological Section.**

**Ethics statement.** This experiments were conducted in accordance with the guideline issued by the State Food and Drug Administration (SFDA of China). The cell lines were cultured and passaged in accordance with the guidelines established by the National Science Council of Republic China. The primary cell lines were purchased from ATCC. All experimental protocols were approved by Academic Committee of Nanjing University.

**Anti-proliferation Assay.** MCF-7 human breast cancer cells was cultured in DMEM/10% fetal bovine serum, in 5% CO\(_2\) water saturated atmosphere at 37 °C. MDA-MB-453 human breast cancer cells was cultured in L-15 medium in 100% air at 37 °C. Cell suspensions (10000/mL) were prepared and 100 μL/well well dispensed into 96-well plates (Costar) giving 1000 cells/well. The plates were returned to the incubator for 24 h to allow the cells to reattact. These compounds were initially prepared at 20 mM in DMSO. Aliquots (200 μL) were diluted into 20 μL culture medium giving 200 μM, and 10 serial dilutions of 3 × prepared. Aliquots (100 μL) of each dilution were added to the wells, giving doses ranging from 100 μM to 0.005 μM. After a further incubated at 37 °C for 24 h in a humidified atmosphere with 5% CO\(_2\), the cell viability was assessed by the conventional 3-(4,5-dime-thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay and carried out strictly according to the manufacturer instructions (Sigma). The absorbance at 590 nm was recorded using LX300 Epson Diagnostic micro-plate reader. Then \( \text{GI}_{50} \) was calculated using SPSS 13.0 software.

**EGFR/HER-2 Inhibitory Assay.** A 1.7 Kb cDNA encoded for human HER-2 cytoplasmic domain (HER-2-CD, amino acids 676–1245) and 1.6 kb cDNA encoded for the EGFR cytoplasmic domain (EGFR-CD, amino acids 645–1186) were cloned into baculoviral expression vectors pBlueBacHis2B and pFASTBacHTc (Huakang Company China), separately. A sequence that encodes (His)\(_6\) was located at the 5′ upstream to the HER-2 and EGFR sequences. SF-9 cells were infected for 3 days for protein expression. SF-9 cell pellets were solubilized at 0 °C in a buffer at pH 7.4 containing 50 mM HEPES, 10 mM NaCl, 1% Triton, 10 μM ammonium molybdate, 100 μM sodium vanadate, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 10 μg/mL pepstatin, and 16 μg/mL benzamidine, HCl for 20 min followed by 20 min centrifugation. Crude extract supernatant was passed through an equilibrated Ni–NTA superflow packed column and washed with 50 mM NaCl, 20 mM HEPES, 10% glycerol and 1 μg/mL each of aprotinin, leupeptin, and pepstatin for 2h. The entire purification procedure was performed at 4 °C or on ice.

Both EGFR and HER-2 kinase assays were set up to assess the level of autophosphorylation based on DELFIA/ Time-Resolved Fluorometry. Compounds \( \text{C1-C20} \) were dissolved in 100% DMSO and diluted to the appropriate concentrations with 25 mM HEPES at pH 7.4. In each well, 10 μL of compound was incubated with 10 μL (12.5 ng for HER-2 or 5 ng for EGFR) of recombinant enzyme (1:80 dilution in 100 mM HEPES) for 10 min at room temperature. Then, 10 μL of 5 × buffer (containing 20 mM HEPES, 2 mM MnCl\(_2\), 100 μM Na\(_2\)VO\(_4\), and 1 mM DTT) and 20 μL of 0.1 mM ATP-50 mM MgCl\(_2\) was added for 1 h. Positive and negative controls were included in each plate by incubation of enzyme with or without ATP-MgCl\(_2\). At the end of incubation, liquid was aspirated and plates were washed three times with wash buffer. A 75 μL (400 ng) sample of europium-labeled anti-phosphotyrosine antibody was added to each well for another 1 h of incubation. After washing, enhancement solution was added and the signal was detected by Victor (Wallac Inc.) with excitation at 340 nm and emission at 615 nm. The percentage of autophosphorylation inhibition by the compounds was calculated using the following equation: 100% - [(negative control)/(positive control - negative control)]. The IC\(_{50}\) was obtained from curves of percentage inhibition with eight concentrations of compound. As the contaminants in the enzyme preparation are fairly low, the majority of the signal detected by the anti-phosphotyrosine antibody is from EGFR or HER-2.

**Flow Cytometry.** MDA-MB-453 cell line was seeded per well in 24-well plates and incubated overnight. Then they were treated with compound \( \text{C20} \) at three different concentrations (0.05 μM, 0.1 μM and 0.2 μM separately). DMSO was chosen as the negative control with a regular dosage of 0.2%. After 24 h, cells were harvested for the apoptosis detection. In brief, collected cells were washed once with PBS and subsequently washed once with binding buffer, and then stained with Annexin V-FITC and propidium iodide (PI) in the binding buffer for 20 min at room temperature in the dark. Apoptotic cells were quantified using a FACScan cytometer (PT. Madagasi
Wallac Victor plate reader using a time delay of 50 or without the presence of the corresponding compounds. The final concentration of drug as 100, 30, 10, 3 μM and incubated in kinase buffer containing ATP and the substrate for 4 h at room temperature with further incubation with compound, cells were harvested and washed with PBS, then lysed in lysis buffer (30 mm Tris, pH 7.5, 150 mm NaCl, 1 mm phenylmethylsulfonyl fluoride, 1 mm Na3VO4, 1% Nonidet P-40, 10% glycerol, and phosphatase and protease inhibitors). After centrifugation at 12,000 g for 5 min, the supernatant was collected as total protein. The concentration of the protein was determined by a BCATM protein assay kit (Pierce, Rockford, IL, USA). The protein samples were separated by 10% SDS–PAGE and subsequently electrotransferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% non-fat milk for 2 h at room temperature. The blocked membrane was probed with the indicated primary antibodies overnight at 4°C, and then incubated with a horse radish peroxidase (HRP)-coupled secondary antibody. P-HER-2 and p-EGFR levels were measured as shown in Fig. 6.

**HER-3 Inhibitory Assay.** A 1.8 Kb cDNA encoded for human HER-3 cytoplasmic domain (HER-3-CD, amino acids 665–1339) was applied to perform the experiment using the same method as EGFR/HER-2.

**VEGFR-2 Inhibitory Assay.** In a 96-well plate, 5 nM/L of either the phosphorylated or nonphosphorylated form of the VEGFR-2 kinase domain was incubated with selected compounds (10-point titration ranging from 4 μM to 0.1 μM), 1 μM/L gastrin substrate, 20 mM/L Tris–HCl, pH 7.5, 10 mM/L MgCl2, 100 mM/L NaCl, 1.5 mM/L EGTA, 1 mM/L DTT, 0.2 mM/L sodium orthovanadate, and 20 μg/mL BSA for 30 min at 25°C. ATP was added at a final concentration of 11.8 μM and incubated for 60 min at room temperature. Eu-labeled antiphosphotyrosine pT66 antibody (Perkin-Elmer) was then used for detection. The fluorescence at 665 nM was measured with a Wallac Victor plate reader using a time delay of 50 μs. The experiment was performed for three independent times and in triplicate each time.

**FAK Inhibitory Assay.** Selected compounds were tested against FAK. In a typical study, human-recombinant full-length FAK was incubated in kinase buffer containing ATP and the substrate for 4 h at room temperature with or without the presence of the corresponding compounds. The final concentration of drug as 100, 30, 10, 3 μg/mL. The remaining ATP in solution was then quantified utilizing the Kinase-Glo-luminescence kit (Promega).

**Safety test section.** **Cytotoxicity test.** The cytotoxic activity in vitro was measured against mouse fibroblast NIH-3T3 cell using the MTT assay. Cells were cultured in a 96-well plate at a density of 5 × 10³ cells and different concentrations of compounds were respectively added to each well. The incubation was permitted at 37°C, 5% CO2 atmosphere for 24 h before the cytotoxicity assessments. 20 μL MTT reagent (4 mg/mL) was added per well 4 h before the end of the incubation. Four hours later, the plate was centrifuged at 1200 rcf for 5 min and the supernatants were removed, each well was added with 200 μL DMSO. The absorbance was measured at a wavelength of 490 nm (OD 490 nm) on an ELISA microplate reader. Three replicate wells were used for each concentration and each assay was measured three times, after which the average of IC50 was calculated. The cytotoxicity of each compound was expressed as the concentration of compound that reduced cell viability to 50% (IC50). The results were summarized in Table 4.

**Hemolysis test.** Hemolytic activity was assayed using fresh capillary human blood. Erythrocytes were collected by centrifuging the blood three times in chilled phosphate buffered saline (PBS at 4°C) at 1000 × g for 10 min. The final pellet was resuspended in PBS to give a 2% w/v solution. Using a microtitre plate, 100 μL of the erythrocyte solution was added to dextran, PLL, stearyl-PLL or stearyl-PLL LDL (1–1000 μg/mL) in a volume of 100 μL. Samples were then incubated for 3 h and the microtitre plate was centrifuged then at 1000 × g for 10 min and the supernatants (100 μL) transferred into a new microtitre plate. Hemoglobin release was determined spectrophotometrically using a microtitre plate reader (absorbance at 550 nm). Results were expressed as the amount of released hemoglobin induced by the compounds as a percentage of the total. Hemolysis test was tested according to the guide of biological evaluation of medical device (SFDFA, China).

**Molecular Modeling.** **Molecular Docking Study.** The three-dimensional structures of the aforementioned compounds were constructed using Chem. 3D ultra 12.0 software (Chemical Structure Drawing Standard; Cambridge Soft corporation, USA (2010)), then they were energetically minimized by using MMFF94 with 5000 iterations and minimum RMS gradient of 0.10. The crystal structures of EGFR domain bound to Erlotinib (PDB Code: 1M17.pdb) and HER-2 domain bound to 03Q (PDB Code: 3P00.pdb) complexes were retrieved from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). All bound waters and ligands were eliminated from the protein and the polar hydrogen was added to the proteins. Molecular docking of all twenty-eight

---

Brosa Inc. JI. Batang Hari NO. 73, Propinsi Sumatera Utara, Indonesia) plotting at least 10,000 events per sample. To quantify the data, the frequencies in all quadrants were analyzed using flowjo software. We regarded cells in the lower right quadrant (Annexin V positive/PI negative) as early apoptotic cells, and cells in upper right quadrant (Annexin V positive/PI positive) as late apoptotic cells and necrotic cells.

**Western Blot.** After incubation with compound, cells were harvested and washed with PBS, then lysed in lysis buffer (30 mm Tris, pH 7.5, 150 mm NaCl, 1 mm phenylmethylsulfonyl fluoride, 1 mm Na3VO4, 1% Nonidet P-40, 10% glycerol, and phosphatase and protease inhibitors). After centrifugation at 12,000 g for 5 min, the supernatant was collected as total protein. The concentration of the protein was determined by a BCATM protein assay kit (Pierce, Rockford, IL, USA). The protein samples were separated by 10% SDS–PAGE and subsequently electrotransferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% non-fat milk for 2 h at room temperature. The blocked membrane was probed with the indicated primary antibodies overnight at 4°C, and then incubated with a horse radish peroxidase (HRP)-coupled secondary antibody. P-HER-2 and p-EGFR levels were measured as shown in Fig. 6.

**BLI assay.** Bio-layer interferometry (BLI). Binding of compounds (labeled; 0.01, 0.05, 0.1, 0.5 μM) to the HER-2 protein (truncated) was measured and analyzed on an Octet Red96 instrument (ForteBio) at room temperature. The buffer-equilibrated streptavidin biosensors were loaded with 100 μg/mL protein. A duplicate set of sensors was incubated in the buffer without protein for a background binding control. The assay was performed in black 96-well plates (Thermo Fisher Scientific) with the total working volume of 0.21 mL per well. The signal was analyzed using a double reference subtraction protocol to subtract the non-specific binding, background, and signal drift caused by sensor variability. The binding event was quantified by the shift of interference pattern of the light. The result was shown in Fig. 7 and the KD was calculated by the Octet Red96 instrument.

**Safety test section.** **Cytotoxicity test.** The cytotoxic activity in vitro was measured against mouse fibroblast NIH-3T3 cell using the MTT assay. Cells were cultured in a 96-well plate at a density of 5 × 10³ cells and different concentrations of compounds were respectively added to each well. The incubation was permitted at 37°C, 5% CO2 atmosphere for 24 h before the cytotoxicity assessments. 20 μL MTT reagent (4 mg/mL) was added per well 4 h before the end of the incubation. Four hours later, the plate was centrifuged at 1200 rcf for 5 min and the supernatants were removed, each well was added with 200 μL DMSO. The absorbance was measured at a wavelength of 490 nm (OD 490 nm) on an ELISA microplate reader. Three replicate wells were used for each concentration and each assay was measured three times, after which the average of IC50 was calculated. The cytotoxicity of each compound was expressed as the concentration of compound that reduced cell viability to 50% (IC50). The results were summarized in Table 4.

**Hemolysis test.** Hemolytic activity was assayed using fresh capillary human blood. Erythrocytes were collected by centrifuging the blood three times in chilled phosphate buffered saline (PBS at 4°C) at 1000 × g for 10 min. The final pellet was resuspended in PBS to give a 2% w/v solution. Using a microtitre plate, 100 μL of the erythrocyte solution was added to dextran, PLL, stearyl-PLL or stearyl-PLL LDL (1–1000 μg/mL) in a volume of 100 μL. Samples were then incubated for 3 h and the microtitre plate was centrifuged then at 1000 × g for 10 min and the supernatants (100 μL) transferred into a new microtitre plate. Hemoglobin release was determined spectrophotometrically using a microtitre plate reader (absorbance at 550 nm). Results were expressed as the amount of released hemoglobin induced by the compounds as a percentage of the total. Hemolysis test was tested according to the guide of biological evaluation of medical device (SFDFA, China).

**Molecular Modeling.** **Molecular Docking Study.** The three-dimensional structures of the aforementioned compounds were constructed using Chem. 3D ultra 12.0 software (Chemical Structure Drawing Standard; Cambridge Soft corporation, USA (2010)), then they were energetically minimized by using MMFF94 with 5000 iterations and minimum RMS gradient of 0.10. The crystal structures of EGFR domain bound to Erlotinib (PDB Code: 1M17.pdb) and HER-2 domain bound to 03Q (PDB Code: 3P00.pdb) complexes were retrieved from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/home.do). All bound waters and ligands were eliminated from the protein and the polar hydrogen was added to the proteins. Molecular docking of all twenty-eight
cCompounds were then carried out using the Discovery Studio (version 3.5) as implemented through the graphical user interface CDocker protocol.

CDocker is an implementation of a CHARMm based molecular docking tool using a rigid receptor, including the following steps:

1. A series of ligands conformations are generated using high temperature molecular dynamics with different random seeds.

2. Random orientations of the conformations are generated by translating the center of the ligand to a specified position within the receptor active site, and making a series of random rotations. A softened energy is calculated and the orientation is kept when it is less than a specified limit. This process repeats until either the desired number of low-energy orientations is obtained, or the test times of bad orientations reached the maximum number.

3. Each orientation is subjected to simulated annealing molecular dynamics. The temperature is heated up to a high temperature then cooled to the target temperature. A final energy minimization of the ligand in the rigid receptor using non-softened potential is performed.

4. For each of the final pose, the CHARMm energy (interaction energy plus ligand strain) and the interaction energy alone are figured out. The poses are sorted according to CHARMm energy and the top scoring (most negative, thus favorable to binding) poses are retained. The whole kinase domain defined as a receptor and the site sphere was selected based on the original ligand binding location, then the original ligand was removed and the ligands prepared by us were placed during the molecular docking procedure. CHARMm was selected as the force field. The molecular docking was performed with a simulated annealing method. The heating steps were 2000 with 700 of heating target temperature. The cooling steps were 5000 with 300 cooling target temperature.

Ten molecular docking poses saved for each ligand were ranked according to their dock score function. The pose with the highest -CDocker energy was chosen as the most suitable pose.

**ADMET Prediction.** Absorption, distribution, metabolism, excretion, and toxicity properties (ADMET) of the 20 novel compounds were calculated using the DS software. The aqueous solubility, blood brain barrier penetration, cytochrome P450 2D6 inhibition, hepatotoxicity, human intestinal absorption and plasma protein binding were predicted using this software.

**QSAR Model.** In the model, 80% (that is 16) of the 20 compounds were utilized as a training set for QSAR modeling. The remaining 20% (that is 4) were chosen as test subset using the same protocol. The selected test compounds were: C5, C8, C10 and C15.

The inhibitory activity of the compounds in literatures [IC\(_{50}\) (mol/L)] was initially changed into the minus logarithmic scale [pIC\(_{50}\) (mol/L)] and then used for subsequent QSAR analysis as the response variable.

In Discovery Studio, the CHARMm force field is applied and the electrostatic potential together with the Van der Waals potential are treated as separate terms. As the electrostatic potential probe, a carbon atom with a radius of 1.73 Å is used as a probe.

A Partial Least-Squares (PLS) model is built using energy grids as descriptors. QSAR models were built by using the Create 3D QSAR Model protocol in Discovery Studio 3.5.

**Statistical analysis.** Statistical analysis was performed with SPSS Version 13.0 statistic software package. Data were expressed as means ± standard deviation (SD). Comparisons between groups were performed with analysis of non-parametric test. A value of P < 0.05 was considered statistically significant.

**References**

1. Kamath, S. & Buolamwini, J. K. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. *J Med Chem* 46, 4657–4668, doi: 10.1021/jm030065n (2003).

2. Seymour, L. Novel anti-cancer agents in development: exciting prospects and new challenges. *Cancer Treat Rev* 25, 301–312, doi: 10.1016/S0305-7372(99)00013-9 (1999).

3. Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. *Nat Rev Cancer* 3, 1062–1074 (2003).

4. Kolibaba, K. S. & Druker, B. J. Protein tyrosine kinases and cancer. *Biochim Biophys Acta* 1333, F217–F248, doi: 10.1016/S0304-419X(97)00022-X (1997).

5. Blume-Jensen, P. & Hunter, T. Oncogenic kinase signaling. *Nature* 411, 355–365, doi: 10.1038/35077225 (2001).

6. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. *Nat Rev Mol cell Biol* 2, 127–137, doi: 10.1038/35052073 (2001).

7. Kim, H. & Muller, W. J. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. *Exp Cell Res* 253, 78–87, doi: 10.1006/excr.1999.4706 (1999).

8. Moscatello, D. K. et al. Epidermal growth factor-2 receptor in cancer therapy. *J Natl Cancer Inst* 91, 1010–1019, doi: 10.1093/jnci/91.16.1010 (1999).

9. Cretella, D. et al. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. *Molecular Cancer* 13, 143, doi: 10.1186/1476-4598-13-143 (2014).

10. Tsigenpy, I. F. et al. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. *Oncotarget* 6, 6029–6039, doi: 10.18632/oncotarget.3472 (2015).

11. Arora, K., Cheng, J. & Nichols, R. A. Nicotinic acetylcholine receptors sensitive to MAPK-linked pathway on prolonged exposure to β-amyloid. *J Bio Chem* 290, 21409–21420, doi: 10.1074/jbc.M111.341462 (2015).

12. Tsumagari, K. et al. Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer. *Cancer Lett* 236, 46–53, doi: 10.1016/j.canlet.2005.07.011 (2015).

13. Qui, Y. G. et al. Downregulating p22phox ameliorates inflammatory response in Angiotensin II-induced oxidative stress by regulating MAPK and NF-κB pathways in ARPE-19 cells. *Scientific Rep* 5, 14362, doi: 10.1038/srep14362 (2015).

14. Khehawuty, S. A., Essapen, S., Seddon, A. M., Fan, Z. & Modjtahedi, H. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. *British J Chem* 113, 1010–1019, doi: 10.1038/bjc.2015.319 (2015).
15. Das, S. et al. Human Epidermal Growth Factor Receptor 2 (HER2) impedes MLK3 kinase activity to support breast cancer cell survival. *J Biol Chem* **290**, 21705–21712, doi: 10.1074/jbc.M115.655563 (2015).

16. Pierpaoli, E. et al. Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. *Carcinogenesis* **36**, 1169–1179, doi: 10.1093/carcin/bgv103 (2015).

17. Muniyan, S. et al. Erbb2-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. *Cellular Signalling* **27**, 2261–2271, doi: 10.1016/j.cellsig.2015.08.002 (2015).

18. Yang, W. et al. Design, modification and 3D QSAR studies of novel naphtalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents. *Bioorg Med Chem* **21**, 1050–1063, doi: 10.1016/j.bmc.2013.01.013 (2013).

19. Yang, M. et al. Synthesis, reactivity, and biological activity of Gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors. *Bioorg Chem* **54**, 3316–3324, doi: 10.1012/ic509298a (2015).

20. Xiong, X. S. et al. Antitumor activity of a new N-substituted thiourea derivative, an EGFR-signaling-targeted inhibitor against a panel of human lung cancer cell lines. *Chemotherapy* **54**, 463–474, doi: 10.1159/000159272 (2008).

21. Lv, P. C., Li, H. Q., Sun, J., Zhou, Y. & Zhu, H. L. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. *Bioorg Med Chem* **18**, 4606–4614, doi: 10.1016/j.bmc.2010.05.034 (2010).

22. Wang, H. H. et al. Synthesis, molecular docking and evaluation of thiazolyl-pyrazole derivatives containing benzodioxide as potential anticancer agents. *Bioorg Med Chem* **21**, 448–455, doi: 10.1016/j.bmc.2012.11.020 (2013).

23. Labussiere, M. et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. *Neurology* **83**, 1200–1206, doi: 10.1212/WNL.0000000000000814 (2014).

24. Luo, Y. et al. Synthesis, biological evaluation, 3D-QSAR studies of novel aryl-2H-pyrazole derivatives as telomerase inhibitors. *Bioorg Med Chem Lett* **23**, 1091–1095, doi: 10.1016/j.bmcl.2012.12.010 (2013).

25. Stamos, J., Słowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. *J Biol Chem* **277**, 46265–46272, doi: 10.1074/jbc.M207135200 (2002).

26. Aertgeerts, K. et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. *J Biol Chem* **286**, 18756–18765, doi: 10.1074/jbc.M110.206193 (2011).

27. Beck, B. & Geppert, T. Industrial applications of in silico ADMET. *J Mol Model* **20**, 2322, doi: 10.1007/s00894-014-2322-5 (2014).

28. Hodgson, J. ADMET-turning chemicals into drugs. *Nature Biotechnology* **19**, 722–726, doi: 10.1038/90761 (2001).

29. Lee, J. Y., Jeong, K. W., Shin, S., Lee, J. U. & Kim, Y. Discovery of novel selective inhibitors of Staphylococcus aureus β-ketoacyl acyl carrier protein synthase III. *Eur J Med Chem* **59**, 2168–2174, doi: 10.1016/j.ejmech.2011.10.052 (2012).

30. He, X., Reeve, A. M., Desai, U. R., Kellogg, G. E. & Reynolds, K. A. 1,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH). *Antimicrob Agents Chemother* **48**, 3093–3102, doi: 10.1128/AAC.48.8.3093-3102.2004 (2004).

31. Kirkpatrick, P. Virtual screening-Gliding to success. *Nat Rev Drug Discov* **3**, 299–299, doi: 10.1038/nrd1364 (2004).

**Acknowledgements**

This work was supported by Natural Science Foundation of Jiangsu Province (No. BK20130554), Major Projects on Control and Rectification of Water Body Pollution (No. 2011ZX07204-001-004), and ‘PCSIRT’ (IRT1020).

**Author Contributions**

B.Y. initiated the idea and completed the chemical part. Y.-S.Y. designed the study and completed the molecular modelling. Y.-S.Y. and N.Y. completed the bioassay. Y.-S.Y., G.L. and H.-L.Z. analyzed the data and wrote the manuscript.

**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Yang, B. et al. Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors. *Sci. Rep.* **6**, 27571; doi: 10.1038/srep27571 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/